

HEMATOLOGIC MALIGNANCIES

Rimini Hotel Savoia | October 2019 | 17th - 18th


October 17th

Chronic Lymphocytic Leukemia Chair: A. Lucchesi, A. Merli

- 09:00 Pathogenesis: Genes and microenvironment **D. Rossi**
09:30 Predictive biomarkers **A. Cuneo**
10:00 Bruton Tyrosin kinases inhibitors **JR Brown**
10:30 Coffe break
11:00 What's the role of Pi3 K inhibition? **L. Scarfò**
11:30 Bcl2 Inhibition **M. Montillo**
12:00 The best sequence of therapy in CLL
in the era of novel agents **JR Brown**

Aggressive Lymphomas Chair: G. Musuraca, M. Tani

- 12:30 Diagnostics, molecular advances and new targets in treating
aggressive lymphomas **S. Pileri**
13:00 How I treat DLBCL in 2019 **G. Musuraca**
13:30 Lunch
14:30 Mantle cell lymphoma: The new treatment algoritm **S. Rule**
15:00 Primary CNS Lymphoma: Diagnosis and treatment **A. Ferreri**
15:30 T cell lymphomas **F. Zaja**
16:00 CAR T Cell and or Transplant in DLBCL **P. Corradini**
Indolent Lymphomas Chair: E. Zuffa, S. Tomassetti
16:40 Marginal zone lymphomas **E. Zucca**
17:10 Waldenstrom macroglobulinemia: All about that **E. Kastritis**
17:40 Follicular lymphoma: Treatment algorithm
and new drugs **F. Morschauser**



October 18th

Acute Lymphoblastic Leukemia Chair: E. Zuffa, S. Tomassetti

- 08:30 Pathogenesis and treatment algorithm in Adult acute
lymphoblastic leukemia **R. Bassan**
09:10 Salvage therapy and MRD **F. Lanza**
09:40 Ph+ and Ph like ALL: From Biology to treatment **O. Ottmann**
10:10 Coffee break

Acute Myeloid Leukemia Chair: F. Lanza, G. Martinelli

- 10:45 Genetic of AML **B. Falini**
11:15 Risk adapted strategies in AML **G. Martinelli**
11:45 Role of the IDH1 and IDH 2 mutations **L. Bullinger**
12:05 FLT3 inhibition in AML **C. Papayannidis**
12:25 The long awaited Return of Mylotarg in AML **A. Venditti**
12:45 The revolution of bcl-2 inhibition...when and how **G. Saglio**
13:05 Lunch
14:10 Older patients with AML **F. Ferrara**
14:40 New techniques and considerations for the role
of transplantation in AML **A. Nagler**

Multiple Myeloma Chair: P. Tosi, C. Cerchione

- 15:10 Molecular Biology in Myeloma **C. Terragna**
15:30 Risk factors and criteria for treatment **F. Gay**
15:50 First line treatments in transplantable patients **E. Zamagni**
16:20 Strategies for transplant-ineligible patients and
relapsed/refractory patients:
The right sequence of treatment and new combinations **SK Kumar**
17:00 CAR T cells in Myeloma **P. Tosi**
17:30 Closing remarks